Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Routine Gene Testing For Plavix Patients Unsupported By Evidence - ACC/AHA

This article was originally published in The Pink Sheet Daily

Executive Summary

While a small minority of cardiologists has embraced genetic testing for clopidogrel, FDA's warning that 2% - 14% of patients may not respond caused pushback from many in the field who argue it is not clear what steps to take when a patient is identified as a poor metabolizer.

You may also be interested in...



Debate On Antiplatelet Gene Testing Continues; First Point-Of-Care Test Filed

The first regulatory application for a point-of-care assay for genotyping patients for response to antiplatelet therapy was submitted at the end of August - if Nanosphere's test is approved, it could make genotyping a more feasible routine tool for guiding therapy for Plavix

Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind

Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS070994

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel